Oncology Biosimilars Market, By Cancer Type, By Product Type, By Distribution Channel, By Geography

Description

Oncology Biosimilars Market is estimated to be valued at USD 9.7 Bn in 2026 and is expected to reach USD 28.5 Bn by 2033, growing at a compound annual growth rate (CAGR) of 16.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 9.7 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	16.60%	2033 Value Projection:	USD 28.5 Bn

The market is undergoing a major transformation owing to the rising prevalence of cancer, increasing demand for affordable biologic therapies, and growing emphasis on expanding access to advanced oncology treatment. Oncology biosimilars including monoclonal antibodies, supportive-care biologics, and therapeutic proteins, enable healthcare systems to reduce treatment costs while maintaining comparable efficacy, safety, quality, and regulatory standards. The market includes a wide array of product applications like breast cancer, colorectal cancer, lung cancer, lymphoma, leukemia, and supportive cancer care.

Patients and healthcare providers are focusing on cost-effective treatment options and broader therapeutic accessibility to improve treatment adherence, ensure continuity of care, and maintain quality of life. Advancements in biologic manufacturing, analytical characterization, and clinical comparability studies are improving product acceptance, especially across hospitals, oncology clinics, and emerging healthcare markets. In addition, the growing use of trastuzumab, bevacizumab, rituximab, pegfilgrastim, and other biosimilar products helps optimize cancer treatment expenditure and patient access, thereby improving clinical outcomes and reducing the overall financial burden on healthcare systems.

Market Dynamics

The market is gaining momentum owing to the increasing global cancer burden, patent expiration of major oncology biologics, and growing pressure to reduce the cost of cancer treatment. Market growth is largely driven by patients, hospitals, oncology centers, and healthcare systems seeking affordable alternatives to reference biologic medicines, particularly for breast cancer, colorectal cancer, lung cancer, non-Hodgkin lymphoma, leukemia, and chemotherapy-induced complications. Comparable clinical efficacy, lower treatment expenditure, expanding regulatory approvals, and increasing physician confidence play a central role in biosimilar adoption, thereby helping broaden treatment access, improve therapy continuity, reduce healthcare spending, and support sustainable cancer care. The rising focus on value-based healthcare, reimbursement optimization, and equitable access to biologic therapies is strengthening demand for oncology biosimilars.

The expiration of exclusivity rights for blockbuster biologics is fueling market growth. This is mainly driven by increasing availability of biosimilar versions of trastuzumab, bevacizumab, rituximab, pegfilgrastim, and filgrastim, alongside greater competition among biologic manufacturers. Product developments involving advanced cell-line engineering, analytical characterization, process optimization, and improved formulation stability help ensure product consistency, meet regulatory comparability requirements, and support reliable therapeutic performance.

The rising demand for cost-efficient cancer care is also propelling the market. Oncologists, hospital pharmacists, regulatory authorities, payers, procurement agencies, biologic manufacturers, and specialty distributors play a crucial role in recommending, approving, purchasing, and supplying oncology biosimilars. As cancer treatment becomes increasingly affordability-focused, the market is expected to benefit from broader reimbursement coverage, stronger tender participation, improved physician education, expanding manufacturing capacity, and the introduction of accessible, clinically comparable, and high-quality biosimilar therapies.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Oncology Biosimilars Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Amgen Inc., Allergan, Plc, Mylan N.V., Samsung Bioepis Co., Ltd., Teva Pharmaceutical Industries Ltd., Pfizer Inc., Celltrion Healthcare, Novartis International AG, Biogen Idec, Inc., and Biocon Limited.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Oncology Biosimilars Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Oncology Biosimilars Market

Market Segmentation

By Cancer Type (Revenue, USD Bn, 2021-2033)
Lung Cancer
Colorectal cancer
Cervical Cancer
Breast Cancer
Kidney cancer
Stomach cancer
Brain Cancer
Others
By Product Type (Revenue, USD Bn, 2021-2033)
Monoclonal Antibody
Immunomodulators
Others
By Distribution Channel (Revenue, USD Bn, 2021-2033)
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Region (Revenue, USD Bn, 2021-2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC
- Israel
- Rest of Middle East
Africa
- South Africa
- Central Africa
- North Africa
Key Players Insights
Amgen Inc.
Allergan, Plc
Mylan N.V.
Samsung Bioepis Co., Ltd.
Teva Pharmaceutical Industries Ltd.
Pfizer Inc.
Celltrion Healthcare
Novartis International AG
Biogen Idec, Inc.
Biocon Limited

Product Code: CMI1305

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Cancer Type
- Market Snapshot, By Product Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Disease Type Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Oncology Biosimilars Market, By Cancer Type, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Colorectal cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Cervical Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Kidney cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Stomach cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Brain Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

5. Global Oncology Biosimilars Market, By Product Type, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Monoclonal Antibody
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Immunomodulators
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

6. Global Oncology Biosimilars Market, By Distribution Channel, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)

7. Global Oncology Biosimilars Market, By Region, 2021 - 2033, (USD Billion)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- Amgen Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Allergan, Plc
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Mylan N.V.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Samsung Bioepis Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Teva Pharmaceutical Industries Ltd.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Pfizer Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Celltrion Healthcare
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Novartis International AG
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Biogen Idec, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Biocon Limited
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views

9. Section

References
Research Methodology
About Us